A trial looking at BAY 2927088 as a treatment for non small cell lung cancer that has spread
Cancer type:
Status:
Phase:
This trial is comparing with a new drug called BAY 2927088 as a first treatment for non small lung cell lung cancer.

- have a change (
mutation ) in a
gene called HER2
- have not had treatment for their cancer
More about this trial
You might have pembrolizumab and for non small cell lung cancer (NSCLC) that has spread. This is
. The chemotherapy drugs you might have include:
Sometimes the cancer gets worse after treatment. So doctors are looking at ways to improve treatment for NSCLC that has spread.
In this trial they are looking at BAY 2927088. It is a new called a tyrosine kinase inhibitor. It works by blocking the activity of proteins called HER2 and EGFR that tell the cancer cells to grow and divide.
Doctors aren’t sure how well it will work for NSCLC. So they are doing this trial to find out more.
In this trial, some people have standard treatment and some people have BAY 2927088.
The main aims of the trial are to find out:
- how well BAY 2927088 works compared to standard treatment
- more about the side effects of BAY 2927088
- how treatment affects
quality of life
Who can enter
The following bullet points are a summary of the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply. You:
- have non small cell lung cancer (NSCLC) that has spread into surrounding tissues (stage 3 cancer) and you can’t have surgery to remove it. Or you have cancer that has spread to other parts of the body. This is stage 4 cancer.
- have a sample of tissue (
biopsy ) from a previous sample that the team can use to do some tests on. Or you are willing to have a new sample taken if a previous sample isn’t available.
- have had a tissue sample taken in the past that shows you have a gene change (
mutation ) in the HER2 gene
- have an area of cancer that the doctor can measure
- are suitable to have cisplatin and pemetrexed or carboplatin and pemetrexed, in combination with pembrolizumab
- can swallow and absorb tablets
- have satisfactory blood test results
- are fit and active but might not be able to do heavy physical work (performance status of 0 or 1)
- are willing to use reliable contraception during the trial and for a period after if there is any chance you or your partner could become pregnant
- are at least 18 years old
Who can’t take part
Cancer related
You cannot join this trial if any of these apply. You:
- have
squamous cell NSCLC
- have a mixture of small cell and non small cell cancer cells
- have cancer that has spread to the brain or spinal cord or the thin tissue layers that cover them. You can take part if you have had treatment, the cancer has been stable for at least 6 weeks and you have stopped taking
steroids or you are taking a low dose.
- have already had
systemic treatment for NSCLC that has spread
- have had treatment that targets HER2 such as poziotinib, trastuzumab deruxtecan or a similar drug in the past. You might be able to take part if you had this type of treatment just before or after surgery as long as you finished this more than 12 months ago.
- have another gene change in the cancer cells and you could have a standard
targeted cancer drug to treat this. Your doctor will know this.
- have had BAY 2927088 or a similar drug in the past
- had
radiotherapy within 21 days of starting trial treatment. This is apart from radiotherapy to the brain. If you have had radiotherapy, any side effects must be better and you have stopped taking steroids.
- have had major surgery in the last 4 weeks or you have surgery planned within 6 months of joining this trial
- are taking an experimental drug or using a device as part of a clinical trial within 4 weeks of joining this trial
- have had another cancer in the last 5 years unless it has been successfully treated and there have been no signs of it since. You can take part if you had successfully treated
carcinoma in situ of the cervix, breast or skin,
early bladder cancer, early prostate cancer or
non melanoma skin cancer .
Medical conditions
You cannot join this trial if any of these apply. You:
- have had a heart attack in the last 6 months or a
significant heart problem that isn’t well controlled with medication. Your doctor checks your heart before you join the trial.
- have had a
stroke or mini stroke in the last 6 months
- have a problem with how your liver or kidneys work
- are having long term steroid treatment unless it is a low dose
- have or have had scarring on the lungs or inflammation of the lungs (
pneumonitis ) that needed treatment in the past
- have had an
organ transplant - have
digestive system problems that means you can’t absorb BAY 2927088
- have a serious wound that isn’t getting better or a
bone fracture - have moderate to severe side effects from past cancer treatments. You can take part if you have hair loss or skin colour changes. You might be able to take part if you have some moderate side effects as long as they are stable. Your doctor will know this.
- have an
autoimmune condition that needed treatment in the last 2 years apart from certain ones. Your doctor will know about this.
- have HIV. You might be able to take part if you are having treatment and it is stable.
- have hepatitis C, active hepatitis B that isn’t well controlled or any other severe infection
- have a significant bleeding problem
- take medication that affects substances in the body called
CYP enzymes within 2 weeks of starting trial treatment or you take these medications regularly for uncontrolled fits. Your doctor can tell you more about this.
- can’t or won’t take folic acid or vitamin B supplements. This only applies if you are in the group having pemetrexed.
- have another medical condition or mental health condition or there is any other reason the team think you won’t be suitable for the trial
Other
You cannot join this trial if any of these apply. You:
- have had a
live vaccination within 30 days of starting treatment. You can take part if you have had the seasonal flu vaccine or the approved Covid-19 vaccines as these aren’t live.
- are allergic to BAY 2927088, any of the standard treatments or anything they contain
- have had a severe allergic reaction to a type of drug called a
monoclonal antibody in the past
- are pregnant or breastfeeding
Trial design
This phase 3 trial is taking place worldwide. The team need 278 people to take part including 7 people from the UK.
It is a randomised trial. A computer puts you into a treatment group. Neither you nor your doctor will be able to decide which group you are in.
There are 2 treatment groups. You have 1 of the following:
- pembrolizumab and chemotherapy (standard treatment)
- BAY 2927088
Pembrolizumab and chemotherapy (standard treatment)
You have treatment in cycles. Each lasts 3 weeks.
You have pembrolizumab as a drip into a vein. You have it once every 3 weeks or once every 6 weeks. This depends on your individual situation. Your doctor can tell you more. You have pembrolizumab for up to 2 years as long as it is working and the side effects aren’t too bad.
You also have chemotherapy with the drugs cisplatin and pemetrexed or carboplatin and pemetrexed. You have this as a drip into a vein once every 3 weeks. You have up to 4 cycles of treatment.
You have chemotherapy and pembrolizumab on the same day.
BAY 2927088
BAY 2927088 is a tablet. You take the tablets twice a day, every day. You have treatment for as long as it is working and the side effects aren’t too bad. You might also decide that you no longer wish to take the treatment. You can say no to carrying on with the treatment if you want to.
The team give you a medication diary. You use it to record when you take your tablets and how many tablets you take.
Samples for research
The researchers ask people in both treatment groups for any samples of cancer tissue () taken as part of your routine care. This also includes samples from when you were diagnosed.
They also ask to take 3 extra tissue samples during the trial. You can say no to this if you don’t want to have this done.
They also ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.
The team plan to use the samples to:
- see how well the treatment is working
- see what happens to BAY 2927088 in the body
- look at
genes to understand more about NSCLC
- look for substances called
biomarkers to help work out why treatment might work for some people and not for others
The team will also ask your permission to store some samples for up to 15 years after the study ends for future research.
Quality of life
The trial team ask you to fill out some questionnaires:
- before you start treatment
- at set times during and after treatment
The questionnaires ask about side effects and how you’ve been feeling. This is called a quality of life study.
Hospital visits
You see the doctor and have tests before you can take part. These include:
- blood tests
- urine tests
- a
physical examination - heart trace (ECG)
- heart scan (echo) or MRI scan of the heart
- CT scan or MRI scan
- eye tests
You might also need to have a bone scan or a PET-CT scan.
You have chemotherapy and pembrolizumab in the hospital outpatient department. You shouldn’t need to stay overnight.
During treatment, you see the doctor regularly. This is for blood tests and to see how you are.
Trial scans
You have a CT scan or MRI scan:
- once every 6 weeks for the first 9 months and then
- every 9 weeks after that
You stop having the trial scans if your cancer gets worse.
Follow up visits
You see the trial team one month after you stop treatment.
If you stopped treatment but your cancer didn’t get worse, you see the trial doctor every 6 to 9 weeks. You continue with the trial scans. This is until your cancer gets worse or you start a new cancer treatment.
A member of the trial team will then contact you every 3 months. This might be at a routine hospital appointment or they may call you. This is to see how you are.
Side effects
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Your doctor will tell you about the possible side effects of treatment and answer any of your questions before you agree to take part.
BAY 2927088 is a new treatment. So we don’t know what all the side effects are. The most common side effects of BAY 2927088 we know about include:
- diarrhoea
- feeling or being sick
- nail changes and skin problems including rash, inflammation, infection, dryness or itching
- loss of appetite
- high levels of liver
enzymes - high levels of an enzyme called amylase
- mouth sores, inflammation or ulcers
- low levels of potassium in the blood
Pembrolizumab can affect the These side effects could happen during treatment or months after treatment has finished. Rarely, these side effects could be life threatening. Your doctor or nurse can explain what these side effects are, the risk of them happening and what to look out for. |
We have information about the following drugs and their side effects:
Location
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Ajay Mehta
Supported by
Bayer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040